-Celltrion, Inc. (KRX:068270) has announced its participation in the United European Gastroenterology (UEG) Week 2026 to be held in Barcelona, Spain, from 17 to 20 October, where it will highlight its portfolio for the treatment of inflammatory bowel disease (IBD), led by Remsima™ SC (subcutaneous infliximab).

The complete infliximab portfolio that will be showcased includes Remsima's™ intravenous (IV) and subcutaneous (SC) formulations as well as the Remsima™ IV liquid formulation, which was launched in Europe earlier this year.¹ In addition, Celltrion will showcase its broadest portfolio for IBD, which includes SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued commitment to expanding treatment options for IBD patients.^2,3

On October 18, Celltrion will host a symposium entitled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," chaired by Professor Peter M. Irving of King's College London, UK, a leading expert in the field of IBD.

In addition, Celltrion will host two MTE sessions at its booth. In the first session, Professor Irina Blumenstein from the University Hospital of Frankfurt (Germany) will present clinical evidence and therapeutic considerations related to Remsima™ SC monotherapy, based on real data and clinical experience.

"UEG Week 2026 provides an opportunity to share clinical evidence and clinical practice experience with healthcare professionals, highlighting the role of Remsima™ SC in addressing diverse treatment needs in IBD," explains Taehun Ha, senior vice president and director for Europe at Celltrion. "We will continue to strengthen our position in the IBD industry as a trusted partner for healthcare professionals around the world."